Seungmin Ha_SCIENTIFIC POSTER 2015

Introduction:

Acute central serous chorioretinopathy has different pathogenic concepts and it has no gold standard treatment. Treatment includes focal laser photocoagulation, PDT, and intravitreal anti-VEGF injection. Focal laser can seal the leaking vessels but it can cause scotoma and develop CNV. PDT can be also treatment option but it can cause RPE alterations, CNV, and choroidal ischemia. Anti-VEGF injection has no long-term positive effect in previous studies. However, its occurrence has mainly been associated with men in their 30s to 40s and many patients want faster recovery. Purpose: To evaluate the short-term efficacy of intravitreal bevacizumab injection(IVB) in acute central serous chorioretinopathy.

Methods:

This retrospective study included 22 eyes with acute central serous chorioretinopathy, which consisted of two groups: the bevacizumab group that received intravitreal bevacizumab injection (1.25mg, 2.0mg or 2.5mg (n = 15)), the observation group that did not any special treatment (n = 7). Best-corrected visual acuity (BCVA) and central macular thickness (CMT) were measured at baseline and 1 month after treatment or observation.

Results:

Mean CMT decreased from 472.2 ± 165.5 μm to 286.2 ± 79.7 μm 1 month after intravitreal bevacizumab injection(IVB) (p=0.003) and 490.9 ± 114.1 μm to 333.7 ± 99.4 in observation group (p=0.001). Mean BCVA improved from 0.68 ± 0.24 to 0.79 ± 0.16 after injection in bevacizumab group (p=0.02) and from 0.74 ± 0.25 to 0.79 ± 0.21 in observation group (p=0.204). There was no significant change in observation group. The loss of BCVA occurred in 1 patient in bevacizumab group (9.1%) and 3 patients in observation group. Complete resolution of SRF was observed only in 1 patient in bevacizumab group.

Conclusions:

Although the CMT decreased siginificantly in both group, the BCVA increased significantly only in bevacizumab group 1 month later. Therefore, Intravitreal bevacizumab injection can be a good treatment option in patients with acute central serous chorioretinopathy who wish to accelerate the healing process.

Contact Details:

Email: seungmin3@gmail.com
Cell Phone: +821072999618